7 completed, 1 recruiting, 1 terminated. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 7, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Abdominal Obesity: new trials by email Literature Review of Abdominal Obesity trials Research Report on Abdominal Obesity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV Tesamorelin, Placebo, Exercise - HIV-1-infection, Frailty | Phase 2 | Recruiting | Massachusetts General Hospital | 100 | 2025-07-10 | 2026-05-19 |
| Effects of Acipimox on Mitochondrial Function in Obesity Acipimox, Placebo - Abdominal Obesity, Insulin Resistance | Phase 2 | Completed | Massachusetts General Hospital | 39 | 2012-05-01 | 2016-03-01 |
| Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity GFT505 80mg, Placebo - Insulin Resistance, Abdominal Obesity | Phase 2 | Completed | Genfit | 22 | 2011-01-01 | 2012-09-24 |
| Grain Exercise Trial - Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss Diet A, Diet B, Physiotherapy - Abdominal Obesity, Cardiovascular Diseases | Phase 2 / Phase 3 | Completed | Lund University | 105 | 2010-08-01 | 2017-06-20 |
| Pilot Study With GFT505 (80mg) in Patients Presenting With Impaired Glucose Tolerance and Abdominal Obesity. GFT505 80mg, Placebo - Impaired Glucose Tolerance, Abdominal Obesity | Phase 2 | Completed | Genfit | 47 | 2009-06-01 | 2011-01-12 |
| Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity GFT505 80mg, Placebo - Atherogenic Dyslipidaemia, Abdominal Obesity | Phase 2 | Completed | Genfit | 96 | 2009-01-01 | 2011-01-07 |
| Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth hormone releasing hormone (GHRH) 1-44, Placebo - Abdominal Obesity, Growth Hormone Deficiency | Phase 2 | Completed | Massachusetts General Hospital | 60 | 2008-07-01 | 2017-12-13 |
| Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension Aliskiren, Amlodipine, Placebo of Aliskiren - Hypertension, Abdominal Obesity | Phase 2 | Terminated | Novartis | 46 | 2007-06-01 | 2014-09-10 |
| Effect of Replacing HFCS With Sucromalt in Subjects With Raised Waist Circumference High Fructose Corn Syrup, Sucromalt - Abdominal Obesity | Phase 2 | Completed | University of Toronto | 28 | 2006-09-01 | 2007-08-14 |
Obesity, Abdominal (9) · Glucose Intolerance (3) · Insulin Resistance (3) · Hypertension (2) · Cardiovascular Diseases (1) · Diabetes Mellitus, Type 2 (1) · Dwarfism, Pituitary (1) · Frailty (1) · Hypertriglyceridemia (1) · Overweight (1) · Stroke (1) · Weight Loss (1)
Body Weight (9) · Nutrition Disorders (9) · Nutritional and Metabolic Diseases (9) · Obesity (9) · Overnutrition (9) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Overweight (8) · Glucose Metabolism Disorders (5) · Metabolic Diseases (5) · Hyperglycemia (3) · Hyperinsulinism (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Endocrine System Diseases (2)
2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (3) · Exercise (2) · tesamorelin (2) · Amlodipine (1) · Ghrelin (1) · Growth Hormone-Releasing Hormone (1) · High Fructose Corn Syrup (1) · Physical Therapy Modalities (1) · Whole Grains (1) · acipimox (1) · aliskiren (1) · sucromalt (1)
Genfit (3) · Massachusetts General Hospital (3) · Lund University (1) · Novartis (1) · University of Toronto (1)
France (3) · United States (3) · Canada (1) · Germany (1) · Romania (1) · Sweden (1) · Tunisia (1)
Kristine M. Erlandson, MD (1) · Lindsay T. Fourman, MD (1) · Staffan Lindeberg, MD PhD (1) · Steven Grinspoon, MD (1) · Steven K. Grinspoon, MD (1) · Thomas MS Wolever, MD, PhD (1)
PMID 23703580, PMID 21816979, PMID 23015655, PMID 23715754, PMID 24178787, PMID 24291224, PMID 26691888, PMID 38639002, PMID 41039470, PMID 42419889
2008 (1), 2009 (1), R01HL085268 (1)